• Coronavirus: Italian vaccine, okay for pre-clinical tests
  • Coronavirus, over 1000 dead in China. WHO: possible vaccine in 18 months

Share

April 30, 2020The partnership between Oxford University and AstraZeneca for the development, production and distribution of the anti-Covid vaccine worldwide "plans to adopt a non-profit model for the duration of the pandemic", that is without profit margins. The IRBM Group announced this, engaged in the development and production of the doses necessary for the next phases of clinical trials.

A study that also speaks Italian
The Advent company from Pomezia, a partner in the development of the anti-Covid vaccine with the Jenner Institute of Oxford University, "continues the activities for the development and production of the doses necessary for the next clinical trial phases". The same company announced this by stressing that, together with the parent company IRBM, "the commitment to continue to put its specific experience and production capacity at the disposal of the program to support the program has already been renewed both to the project partners and to the Italian Government. the subsequent stages of vaccine development, validation and production ".  

320 volunteers
The experimental Covid vaccine developed by Oxford University and Advent-Irbm, ChAdOx1, has so far been administered to over 320 healthy volunteers and has been "safe and well tolerated". This is underlined by the multinational AstraZeneca. Clinical trials of the potential vaccine began last week on over 500 healthy volunteers in 5 centers in England. The results of this first phase are expected by May.

Perhaps the first stock in 
December "By December, if all the tests give the positive results we hope for, there will be a first stock of anti-Covid vaccine available to start vaccinating some of the more fragile categories." This was stated by the president of Irbm Pietro Di Lorenzo, an Italian company that collaborates with the Jenner Institute of Oxford University for the testing of the vaccine. In June, if the first phase of testing on 500 healthy volunteers gives positive results, the further phase of testing on 5000 subjects will begin.